Pfizer Inc. (ETR:PFE)
22.07
+0.12 (0.52%)
Nov 24, 2025, 5:35 PM CET
Pfizer Revenue
Pfizer had revenue of $16.65B USD in the quarter ending September 28, 2025, a decrease of -5.91%. This brings the company's revenue in the last twelve months to $62.79B, up 3.90% year-over-year. In the year 2024, Pfizer had annual revenue of $63.63B with 6.84% growth.
Revenue (ttm)
$62.79B
Revenue Growth
+3.90%
P/S Ratio
2.31
Revenue / Employee
$775.14K
Employees
81,000
Market Cap
123.81B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 63.63B | 4.07B | 6.84% |
| Dec 31, 2023 | 59.55B | -41.62B | -41.14% |
| Dec 31, 2022 | 101.18B | 19.89B | 24.46% |
| Dec 31, 2021 | 81.29B | 39.64B | 95.16% |
| Dec 31, 2020 | 41.65B | 746.00M | 1.82% |
| Dec 31, 2019 | 40.91B | 80.00M | 0.20% |
| Dec 31, 2018 | 40.83B | -11.72B | -22.31% |
| Dec 31, 2017 | 52.55B | -278.00M | -0.53% |
| Dec 31, 2016 | 52.82B | 3.97B | 8.13% |
| Dec 31, 2015 | 48.85B | -754.00M | -1.52% |
| Dec 31, 2014 | 49.61B | -1.98B | -3.84% |
| Dec 31, 2013 | 51.58B | -3.07B | -5.62% |
| Dec 31, 2012 | 54.66B | -6.38B | -10.45% |
| Dec 31, 2011 | 61.04B | -4.13B | -6.34% |
| Dec 31, 2010 | 65.17B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bayer Aktiengesellschaft | 45.87B |
| Siemens Healthineers AG | 23.38B |
| Fresenius SE & Co. KGaA | 22.45B |
| Merck KGaA | 21.27B |
| Fresenius Medical Care AG | 19.64B |
| Sartorius Aktiengesellschaft | 3.52B |
| Fielmann Group AG | 2.42B |
| Carl Zeiss Meditec AG | 2.18B |
Pfizer News
- 3 days ago - Pfizer : FDA Oks PADCEV + Keytruda Combo For Cisplatin-Ineligible Muscle-Invasive Bladder Cancer - Nasdaq
- 3 days ago - Pfizer Inc. (PFE) Completes Significant Public Offering of Notes - GuruFocus
- 3 days ago - Growth is your best defense in any environment, says Jim Cramer - CNBC
- 3 days ago - Jim Cramer circles back on dependable high-yield stocks - CNBC
- 3 days ago - As the market fluctuates, Jim Cramer names three lower risk stocks with high dividends - CNBC
- 3 days ago - Why Are Shares of Pfizer Up Today? - Benzinga
- 3 days ago - Pfizer (PFE) Gains FDA Approval for New Bladder Cancer Treatment - GuruFocus
- 3 days ago - U.S. FDA Approves PADCEV plus Keytruda for Certain Patients with Bladder Cancer - Wallstreet:Online